/XSPRAY.ST
XSPRAY.ST Stock - Xspray Pharma AB (publ)
Healthcare|BiotechnologySTO
$31.20+0.32%
+$0.10 (+0.32%) • Dec 23
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $34.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XSPRAY.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.89 – $31.51
TARGET (TP)$35.88
STOP LOSS$28.70
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.36
52W High$64.10
52W Low$23.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-8,547,000 | $-9,194,000 | $-9,532,000 | $-8,870,000 | $-1,411,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-283,236,000 | $-181,734,000 | $-133,073,000 | $-97,953,000 | $-53,457,000 |
| Net Income | $-285,523,000 | $-179,667,000 | $-130,267,000 | $-96,702,000 | $-52,303,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-8.62 | $-6.76 | $-6.13 | $-4.98 | $-3.01 |
Company Overview
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XSPRAY.STBeat Rate
40%
Last 10 quarters
Avg Surprise
-8.5%
EPS vs Estimate
Beats / Misses
4/6
Last 12 quarters
Latest EPS
$-1.25
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
-5.8%
$-1.64vs$-1.55
Q4 24
-75.5%
$-2.44vs$-1.39
Q1 25
-29.7%
$-2.36vs$-1.82
Q2 25
+37.0%
$-1.14vs$-1.81
Q4 25
+24.1%
$-1.25vs$-1.65
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | $-1.65 | $-1.25 | +24.1% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-1.81 | $-1.14 | +37.0% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-1.82 | $-2.36 | -29.7% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-1.39 | $-2.44 | -75.5% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-1.55 | $-1.64 | -5.8% | ✗ MISS |
Q2 2024 | May 8, 2024 | — | $-2.17 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-1.85 | — | — |
Q4 2023 | Nov 8, 2023 | — | $-1.59 | — | — |
Q3 2023 | Aug 2, 2023 | — | $-2.27 | — | — |
Q2 2023 | May 4, 2023 | — | $-1.50 | — | — |
Q1 2023 | Feb 15, 2023 | $-2.14 | $-2.48 | -15.9% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-2.53 | $-1.39 | +45.1% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-0.93 | $-1.40 | -50.5% | ✗ MISS |
Q2 2022 | May 6, 2022 | $-2.53 | $-0.92 | +63.6% | ✓ BEAT |
Q1 2022 | Feb 18, 2022 | $-1.48 | $-2.62 | -77.0% | ✗ MISS |
Q4 2021 | Oct 26, 2021 | — | $-0.73 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-0.89 | — | — |
Q2 2021 | May 6, 2021 | — | $-0.73 | — | — |
Q1 2021 | Feb 25, 2021 | — | $-0.89 | — | — |
Q4 2020 | Nov 20, 2020 | — | $-0.66 | — | — |
Latest News
Loading news...
Frequently Asked Questions about XSPRAY.ST
What is XSPRAY.ST's current stock price?
Xspray Pharma AB (publ) (XSPRAY.ST) is currently trading at $31.20 per share. The stock has moved +0.32% today.
What is the analyst price target for XSPRAY.ST?
No analyst price targets are currently available for this stock.
What sector is Xspray Pharma AB (publ) in?
Xspray Pharma AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is XSPRAY.ST's market cap?
Xspray Pharma AB (publ) has a market capitalization of $1.14 billion, making it a small-cap company.
Does XSPRAY.ST pay dividends?
No, Xspray Pharma AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
CANTA.ST
Cantargia AB (publ)
$4.09
Mkt Cap: $1.0B
IBT-B.ST
Infant Bacterial Therapeutics AB (publ)
$49.00
Mkt Cap: $0.6B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
ITECH.ST
I-Tech AB
$52.80
Mkt Cap: $0.6B
ONCO.ST
Oncopeptides AB (publ)
$4.57
Mkt Cap: $1.0B
ORX.ST
Orexo AB (publ)
$27.30
Mkt Cap: $0.9B
SEDANA.ST
Sedana Medical AB (publ)
$9.92
Mkt Cap: $1.0B
SEZI.ST
Senzime AB (publ)
$5.26
Mkt Cap: $0.8B
SYNACT.ST
SynAct Pharma AB
$23.80
Mkt Cap: $1.3B
Explore stocks similar to XSPRAY.ST for comparison